87P an Artificial Neural Network System to Predict the Response to Sintilimab Based on the RNA Data of ORIENT-3 Study

ORIENT-3 was an open-label, multicenter, randomized controlled phase III study that recruited patients with stage ⅢB/ⅢC/Ⅳ squamous-cell non-small cell lung cancer (sqNSCLC) after failure with first-line platinum-based chemotherapy, which had response records and RNA data. This study used the RNA data of ORIENT-3 study to construct an artificial neural network (ANN) system to predict the response to sintilimab for patients with sqNSCLC.